vs

Side-by-side financial comparison of Bioceres Crop Solutions Corp. (BIOX) and PAMT CORP (PAMT). Click either name above to swap in a different company.

PAMT CORP is the larger business by last-quarter revenue ($141.3M vs $77.6M, roughly 1.8× Bioceres Crop Solutions Corp.). Bioceres Crop Solutions Corp. runs the higher net margin — -9.6% vs -20.7%, a 11.1% gap on every dollar of revenue. On growth, PAMT CORP posted the faster year-over-year revenue change (-15.1% vs -16.8%). Over the past eight quarters, Bioceres Crop Solutions Corp.'s revenue compounded faster (-8.4% CAGR vs -12.0%).

Bioceres Crop Solutions Corp is a global agricultural technology firm that develops and commercializes sustainable crop solutions including drought-tolerant seed traits, biofertilizers, and biopesticides. It serves farmers across South America, North America, Europe and Asia-Pacific, focusing on raising crop yields while reducing the environmental footprint of agricultural activities.

BIOX vs PAMT — Head-to-Head

Bigger by revenue
PAMT
PAMT
1.8× larger
PAMT
$141.3M
$77.6M
BIOX
Growing faster (revenue YoY)
PAMT
PAMT
+1.7% gap
PAMT
-15.1%
-16.8%
BIOX
Higher net margin
BIOX
BIOX
11.1% more per $
BIOX
-9.6%
-20.7%
PAMT
Faster 2-yr revenue CAGR
BIOX
BIOX
Annualised
BIOX
-8.4%
-12.0%
PAMT

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
BIOX
BIOX
PAMT
PAMT
Revenue
$77.6M
$141.3M
Net Profit
$-7.4M
$-29.3M
Gross Margin
46.8%
Operating Margin
9.3%
-27.0%
Net Margin
-9.6%
-20.7%
Revenue YoY
-16.8%
-15.1%
Net Profit YoY
-20.2%
7.4%
EPS (diluted)
$-0.12
$-1.38

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BIOX
BIOX
PAMT
PAMT
Q4 25
$141.3M
Q3 25
$77.6M
$150.3M
Q2 25
$151.1M
Q1 25
$60.6M
$155.3M
Q4 24
$98.8M
$166.5M
Q3 24
$93.3M
$182.6M
Q2 24
$182.9M
Q1 24
$84.0M
$182.6M
Net Profit
BIOX
BIOX
PAMT
PAMT
Q4 25
$-29.3M
Q3 25
$-7.4M
$-5.6M
Q2 25
$-9.6M
Q1 25
$-1.6M
$-8.1M
Q4 24
$605.2K
$-31.6M
Q3 24
$-6.2M
$2.4M
Q2 24
$-2.9M
Q1 24
$9.8M
$281.0K
Gross Margin
BIOX
BIOX
PAMT
PAMT
Q4 25
Q3 25
46.8%
Q2 25
Q1 25
39.4%
Q4 24
42.0%
Q3 24
40.2%
Q2 24
Q1 24
50.8%
Operating Margin
BIOX
BIOX
PAMT
PAMT
Q4 25
-27.0%
Q3 25
9.3%
-3.8%
Q2 25
-7.3%
Q1 25
1.5%
-5.9%
Q4 24
14.5%
-22.6%
Q3 24
2.5%
1.3%
Q2 24
-0.4%
Q1 24
15.7%
-0.4%
Net Margin
BIOX
BIOX
PAMT
PAMT
Q4 25
-20.7%
Q3 25
-9.6%
-3.7%
Q2 25
-6.4%
Q1 25
-2.6%
-5.2%
Q4 24
0.6%
-19.0%
Q3 24
-6.6%
1.3%
Q2 24
-1.6%
Q1 24
11.6%
0.2%
EPS (diluted)
BIOX
BIOX
PAMT
PAMT
Q4 25
$-1.38
Q3 25
$-0.12
$-0.27
Q2 25
$-0.46
Q1 25
$-0.02
$-0.37
Q4 24
$0.00
$-1.44
Q3 24
$-0.10
$0.11
Q2 24
$-0.13
Q1 24
$0.14
$0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BIOX
BIOX
PAMT
PAMT
Cash + ST InvestmentsLiquidity on hand
$15.5M
$83.7M
Total DebtLower is stronger
$333.9M
Stockholders' EquityBook value
$288.3M
$210.5M
Total Assets
$734.9M
$697.9M
Debt / EquityLower = less leverage
1.59×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BIOX
BIOX
PAMT
PAMT
Q4 25
$83.7M
Q3 25
$15.5M
$115.6M
Q2 25
$117.3M
Q1 25
$38.5M
$102.7M
Q4 24
$29.2M
$110.7M
Q3 24
$32.3M
$92.3M
Q2 24
$114.0M
Q1 24
$16.4M
$125.8M
Total Debt
BIOX
BIOX
PAMT
PAMT
Q4 25
$333.9M
Q3 25
Q2 25
Q1 25
Q4 24
$325.6M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
BIOX
BIOX
PAMT
PAMT
Q4 25
$210.5M
Q3 25
$288.3M
$239.5M
Q2 25
$244.9M
Q1 25
$345.0M
$269.6M
Q4 24
$346.3M
$277.5M
Q3 24
$346.0M
$308.9M
Q2 24
$306.7M
Q1 24
$348.5M
$314.6M
Total Assets
BIOX
BIOX
PAMT
PAMT
Q4 25
$697.9M
Q3 25
$734.9M
$715.2M
Q2 25
$707.9M
Q1 25
$798.2M
$712.6M
Q4 24
$835.2M
$741.7M
Q3 24
$827.3M
$756.7M
Q2 24
$733.5M
Q1 24
$836.1M
$746.4M
Debt / Equity
BIOX
BIOX
PAMT
PAMT
Q4 25
1.59×
Q3 25
Q2 25
Q1 25
Q4 24
1.17×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BIOX
BIOX
PAMT
PAMT
Operating Cash FlowLast quarter
$14.4M
$-5.8M
Free Cash FlowOCF − Capex
$-25.0M
FCF MarginFCF / Revenue
-17.7%
Capex IntensityCapex / Revenue
13.6%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-23.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BIOX
BIOX
PAMT
PAMT
Q4 25
$-5.8M
Q3 25
$14.4M
$5.9M
Q2 25
$12.2M
Q1 25
$23.3M
$5.0M
Q4 24
$-5.4M
$15.2M
Q3 24
$5.2M
$15.5M
Q2 24
$18.7M
Q1 24
$-17.4M
$9.6M
Free Cash Flow
BIOX
BIOX
PAMT
PAMT
Q4 25
$-25.0M
Q3 25
$2.5M
Q2 25
$5.9M
Q1 25
$-6.8M
Q4 24
$-39.9M
Q3 24
$-33.6M
Q2 24
$4.1M
Q1 24
$-12.2M
FCF Margin
BIOX
BIOX
PAMT
PAMT
Q4 25
-17.7%
Q3 25
1.7%
Q2 25
3.9%
Q1 25
-4.4%
Q4 24
-24.0%
Q3 24
-18.4%
Q2 24
2.2%
Q1 24
-6.7%
Capex Intensity
BIOX
BIOX
PAMT
PAMT
Q4 25
13.6%
Q3 25
2.3%
Q2 25
4.2%
Q1 25
7.6%
Q4 24
33.1%
Q3 24
26.9%
Q2 24
8.0%
Q1 24
12.0%
Cash Conversion
BIOX
BIOX
PAMT
PAMT
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
-8.85×
Q3 24
6.44×
Q2 24
Q1 24
-1.78×
34.11×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BIOX
BIOX

Segment breakdown not available.

PAMT
PAMT

Freight Transportation Service$123.1M87%
Fuel Surcharge$18.2M13%

Related Comparisons